As multidrug resistance is a key determinant of patient survival, the future identification of FOXA1-regulated genes responsible for multidrug resistance will be crucial for the development of targeted therapies and reduction of breast cancer mortality. The gene discussed is FOXA1; the disease is breast carcinoma.